Prelude Therapeutics spotlights JAK2, KAT6A programs and potential $100M Incyte option

Prelude Therapeutics spotlighted its JAK2 and KAT6A programs, including a potential $100 million option with Incyte. The company highlighted these pipeline programs and the Incyte option in its presentation.

Detected & updated continuously · Source: Nebula